
Opinion|Videos|May 23, 2024
Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment
Author(s)Anjali Tiku Owens, MD
A expert cardiologist delves into the insights gained from clinical trials assessing Cardiac Myosin inhibitors (CMIs) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), with a particular focus on the EXPLORER-HCM trial, which investigated the efficacy and safety of mavacamten in managing oHCM.
Advertisement
Episodes in this series

- What have we learned from clinical trials evaluating CMI’s for oHCM?
Hutt et al 2024
- Mavacamten: Outcomes; focused on feel and function
Olivotto et al 2020 ,Maron et al 2023 - Longer-term outcomes of the VALOR-HCM RCT
Desai et al 2023 - MAVA-LTE
- Aficamten: phase 2 REDWOOD-HCM soon to be completed, phase 3 trial SEQUIOA-HCM.
Masri et al 2022 ,Maron et al 2023
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Libre Duo 10 Day Authorized as First Glucose-Ketone Monitor for Diabetes
2
Psoriasis Awareness & Action Month: New Oral Drugs and Other Developments
3
FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer
4
TMS Sessions Reduced From 38 Minutes to 3, With Jonathan Downar, MD, PhD
5








































































